VCLS is a global product development consultancy, which guides Biotechnology, Medtech, and Pharmaceutical manufacturers throughout product development and commercialization. From discovery to patients, VCLS assists innovators to design product development strategies that optimize clinical development to drive commercial success, through an understanding of both regulators and payers.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
Our research at the Wellcome Trust Sanger Institute builds understanding of gene function in health and disease as well as creating resources of lasting value to biomedical research. . . We study diseases that have an impact on health globally by investigating genomes. Building on our past achievements and based on priorities that exploit the unique expertise of our Faculty of researchers, we will lead global efforts to understand the biology of genomes. We are convinced of the importance of making this research available and accessible for all audiences.
WuXi AppTec is a leading open-access R&D capability and technology platform with operations in China, USA, Germany and Iceland. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule, biologics, cell therapy and gene therapy, medical device testing, and molecular testing and genomics, WuXi is enabling more than 2000 collaborators from more than 30 countries to bring innovative healthcare products to patients.
Xampla is a materials innovation company unlocking the power of plants to create natural materials to change the world. Their platform technology powers a variety of applications including microencapsulation to enhance performance and Morro™ materials: world-first materials designed to eliminate the world’s most polluting plastics.
We take our inspiration, and our name, from the principle of exaptation – the concept that a trait which evolved for one purpose can be harnessed to serve an entirely different function.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.
ZAGENO transforms lab supply procurement with the industry’s largest AI-powered marketplace, featuring over 40 million products from 5,300+ global suppliers. Scientists, lab managers, and procurement teams rely on ZAGENO’s all-in-one platform for painless lab supply procurement that optimizes budgets and enhances productivity, while suppliers gain a powerful sales channel. With automated order and delivery tracking, custom workflows, real-time spend analytics, and offloaded supplier management, ZAGENO empowers labs of all sizes to achieve full lab supply ordering automation. Founded in 2015, ZAGENO is headquartered in the U.S., with offices across Europe and Asia. Learn more at https://www.zageno.com